Mutation in PIK3CA is one of the most common events in breast cancer[78,79] and hyperactivation of the PI3K/AKT pathway has long been thought to be a major downstream mechanism of resistance to HER2-targeted therapies[3,80] as well as escape from hormone dependence in ER+ breast cancer[81]. Here, ERBB2 is linked to breast carcinoma.